Setting new standards in information exchange for the pharmaceutical and biotech industry
Expert Citi Analyst Dr Andrew Baum to Deliver Keynote at IO360° in February 2018
August 10, 2017
We are delighted to announce that Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research, Citi, will be the keynote speaker on the Investor Relations in Immunotherapy Plenary Session at the 4th annual Immuno-Oncology 360° program on February 7-9, 2018. Dr Baum’s keynote will provide an in-depth evaluation and forecast of the immuno-oncology (IO) space. He will also share his perspective as part of an investor roundtable on the role of IO within large pharma.
Dr Baum has a deep strategic insight into the global healthcare value chain, as well as a broad network of contacts throughout the industry. He was one of the earliest commentators to highlight to investors the deep structural deficiencies of the historic operating structure and the need to evolve towards a radically different model.
“IO360° continues to help the IO community stay at the forefront of the most relevant research and developments by featuring industry experts, such as Dr Baum, who have their fingers on the pulse of cancer immunotherapy,” says conference director Kate Woda. “As the keynote on the investor relations plenary session, Dr Baum’s insight will help to foster collaboration between the different parties working in all aspects of cancer immunotherapy.”
The next IO360° summit will take place on February 7-9, 2018 in New York City and will cover the full spectrum of IO research and development, Including preclinical, translational, clinical, emerging technologies, business aspects, investor relations and trends in the field.